ClinicalTrials.gg
RecruitingNCT07586943Updated Sep 11, 2026

SKB118 Injection in Advanced Solid Tumors

A Phase 1/2 interventional study of SKB118 Injection and SKB118+SKB264 in Advanced Solid Tumors, sponsored by Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.. Recruiting at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-09-11.

Sponsored by Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (part of Sichuan Kelun Pharmaceutical Co.,Ltd.) · Phase 1/2, Interventional, and Treatment

From the registry’s dates

  • Started Jun 2026; still recruiting 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
530
Allocation
Non-randomized
Ages
18 Years to 75 Years
Sex
All
01

Study summary

This is a multicenter, open-label, Phase I/II clinical study. The study is divided into two parts, the SKB118 monotherapy study and the SKB118 in combination with SKB264 study.

Read the detailed description

Part 1: SKB118 Monotherapy Study To evaluate the safety, tolerability, PK characteristics, immunogenicity, and efficacy of SKB118 in participants with advanced solid tumors. The study includes a Phase I dose escalation stage, a Phase I dose expansion stage, and a Phase II indication expansion stage.

Part 2: SKB118 in Combination with SKB264 Study To evaluate the safety, tolerability, PK characteristics, immunogenicity, and efficacy of SKB118 in combination with SKB264 in participants with advanced solid tumors. This part includes a Phase I combination therapy dose escalation stage, a Phase I combination therapy dose expansion stage, and a Phase II combination therapy indication expansion stage.

02

Conditions studied

  • Advanced Solid Tumors
03

In context

Lead sponsor

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. is the lead sponsor of 55 studies on the registry; 33 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Participants voluntarily joined this study and signed an form.
  2. The age at the time of signing the informed consent form must be between 18 and 75 years.
  3. Participants with or cytologically confirmed advanced solid tumors who have failed standard therapy, have no standard therapy available, or are intolerant to standard therapy.
  4. Participants should provide tumor tissue samples for biomarker testing as much as possible.
  5. Researchers evaluated based on (RECIST) Version 1.1 that there is at least one present.
  6. (ECOG) score is 0 or 1.
  7. Expected survival period ≥ 12 weeks.
  8. Participants have sufficient bone marrow, liver, kidney, and coagulation functions.
  9. Male and female participants must agree to use highly effective methods during the study period.

Exclusion criteria

Exclusion Criteria:

  1. Participants known to have meningeal , brainstem metastasis, spinal cord metastasis and/or compression, and active central nervous system (CNS) metastasis.
  2. Patients with other malignant tumors within 3 years before the first administration.
  3. There are serious heart or vascular diseases or high-risk factors present.
  4. According to researchers' judgment, it is an uncontrollable systemic disease.
  5. There are pleural effusion, pericardial effusion, or ascites with clinical symptoms or requiring repeated drainage (>1 time/week).
  6. History of interstitial lung disease or non infectious pneumonia.
  7. There are other lung diseases that may interfere with drug-related pulmonary toxicity.
  8. There is a risk of developing esophagotracheal fistula or esophageal pleural fistula, or tumor invasion or compression of surrounding important organs and blood vessels accompanied by related clinical symptoms.
  9. Screening imaging shows that the tumor encases important blood vessels or exhibits obvious necrosis or cavities, and the investigator determines that study enrollment would pose a risk of bleeding.
  10. Previous or concurrent gastrointestinal perforation, surgical and wound healing complications, and bleeding events.
  11. The toxicity of previous anti-tumor treatments has not been relieved, defined as the toxicity has not recovered to (CTCAE) Version 6.0 grade 0 or 1.
  12. Have experienced ≥ Grade 3 immune-related adverse events (irAEs) during prior immunotherapy.
  13. Serious infection occurred within 4 weeks before the first administration.
  14. Active or C, or simultaneous infection with Hepatitis B virus(HBV) and virus(HCV).
  15. (HIV) test is positive or there is a history of acquired immunodeficiency syndrome (AIDS); Known active syphilis infection.
  16. Known active pulmonary tuberculosis.
  17. Known history of allogeneic organ transplantation or hematopoietic stem cell transplantation.
  18. History of allergy to the product or any of its components or severe to other monoclonal antibodies.
  19. Having an active disease that required systemic treatment within the past two years.
  20. Active or prior history of confirmed inflammatory bowel disease.
  21. Currently using or having recently used aspirin therapy.
  22. Received oral or parenteral anticoagulants or thrombolytic agents within 2 weeks prior to the first dose.
  23. Previous treatment with antibodies or drugs targeting T-cell co- stimulation or checkpoint pathways, as well as cell therapy.
  24. Received chemotherapy, immunotherapy, biological therapy, or other large molecule anti-tumor drugs within 4 weeks before the first administration.
  25. Within 6 months prior to the first administration, lung lesions received radiation therapy with a total dose greater than 30 Gray.
  26. Have undergone major surgical procedures or suffered serious injuries within 4 weeks prior to the first administration of medication.
  27. Those who have received treatment with other clinical investigational drugs within 4 weeks prior to their first administration.
  28. Individuals who have previously received anti-tumor vaccines or have received any active vaccines within 4 weeks prior to their first treatment with the investigational drug.
  29. Participants who received systemic therapy or other drugs with>10 mg/day prednisone within 2 weeks prior to the first dose.
  30. Pregnant or lactating women.
  31. Participants with a known history of mental illness or substance abuse are unable to cooperate in completing the study.
  32. Suffering from local or systemic diseases caused by non malignant tumors, or diseases or symptoms secondary to tumors, which may affect compliance.
  33. Any condition that the researcher deems to interfere with the evaluation of the investigational drug, the safety of participants, or the interpretation of research results, or any other condition that the researcher deems unsuitable for participation in this study.

Exclusion Criteria for Part 2 34) Documented severe dry eye syndrome, severe meibomian gland disease and/or blepharitis, or a history of corneal disorder that hinders/delays corneal healing.

35) Prior treatment with TROP2-targeted therapy, and any drug therapy containing a topoisomerase I target.

36) Participants who require systemic use of strong inhibitors or inducers of within 2 weeks before the first dose and during the study.

Terms in these criteria, in plain language(17)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
530 participants (estimated)

Study arms

  • Experimental
    SKB118 Injection monotherapy

    Subject will be dosed with SKB118 monotherapy every 3 weeks(q3w)

    Drug: SKB118 Injection

  • Experimental
    SKB118 in combination with SKB264

    Subject will be dosed with SKB118 combined with SKB264 every 2 weeks(q2w)

    Drug: SKB118+SKB264

Interventions

06

What researchers measure

Primary outcomes

  1. Number of subjects achieving Dose-limiting toxicity (DLT)

    DLT is defined as an adverse event (AE) that meets protocol-defined DLT criteria during DLT observation period (within 21 days after the first dose for q3w dosing frequency; within 28 days after the first dose for q2w dosing frequency) and is at least possibly related to the study drug.

    Time frame: From date of initial dose until up to 21 days after the first dose for q3w dosing frequency; or up to 28 days after the first dose for q2w dosing frequency

  2. Objective response rate (ORR)

    The sum of the number of cases with Complete Response (CR) and Partial Response (PR) in all treated tumor patients (CR + PR) divided by the total number of cases.

    Time frame: Up to approximately 3 years

Secondary outcomes

  1. Progression Free Survival (PFS)

    Time from start of treatment to progression of disease (PD) or death, whichever occurs first, in patients with tumors.

    Time frame: Up to approximately 3 years

  2. Duration of Response (DOR)

    Time from the start of the first assessment of CR or PR in tumor patients to PD or death due to any reason.

    Time frame: Up to approximately 3 years

  3. Overall Survival (OS)

    Time from start of treatment to death due to any reason.

    Time frame: Up to approximately 3 years

  4. Maximum observed plasma concentration (Cmax) of SKB118

    Pharmacokinetic (PK) parameters of SKB118

    Time frame: Up to approximately 2 years

  5. Maximum observed plasma concentration (Cmax)of SKB264-ADC,SKB264-TAB and free KL610023

    Pharmacokinetic (PK) parameters of SKB264

    Time frame: Up to approximately 2 years

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jun 2026 (actual). Primary completion is estimated for Dec 2029, 42 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
May 7, 2026
First posted
May 14, 2026
StartActual
Jun 1, 2026
Primary completionEst.
Dec 2029
CompletionEst.
Dec 2030
Last update
Sep 11, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 11, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07586943
Responsible party
Sponsor
First posted
May 14, 2026
Start date
Jun 1, 2026
Primary completion
Dec 2029 (estimated)
Completion
Dec 2030 (estimated)
Last update
Sep 11, 2026

Study contacts

Yina Diao
Contact
diaoyina@kelun.com
86-028-67252634

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Anti-PD-1/Anti-VEGF-A Bispecific Antibody CR-001 · Sacituzumab tirumotecan

Start the discussion